This includes reduced CSF levels indicative of progression of clinically isolated syndrome to definitive MS [72], increased CSF levels in patients with low grade gliomas [73] and in patients with secondary progressive MS [74] as well as decreased CSF fetuin-A in patients with Alzheimer ́s disease [58]. This evidence concerns the gene AHSG and myeloid sarcoma.